2021年2月21日 · This phase I study assessed the safety, tolerability, preliminary antitumor activity, and preliminary biomarkers of ABBV-428, a first-in-class, mesothelin-targeted, bispecific antibody designed for tumor microenvironment-dependent …

The results from our study of LB-1 were used to develop a human cross-reactive bispecific molecule (ABBV-428) that targeted human CD40 and mesothelin. ABBV-428 demonstrated enhanced activation of antigen-presenting cells and T cells upon binding to cell-surface mesothelin, and inhibition of cultured or implanted PC3 tumor cell growth after ...

ABBV-428 represents a class of bispecific molecules with conditional activity dependent on the binding of a tumor-specific antigen, and such activity could potentially maximize antitumor potency while limiting systemic toxicity in clinical studies.

ABBV-428 is a bispecific antibody that targets mesothelin via a C-terminal single-chain variable fragment flanking Fc-modified human IgG1 and CD40 via an N-terminal single-chain variable fragment.

2020年8月15日 · Background: ABBV-428 is a first-in-class bispecific antibody against CD40 and MSLN designed to stimulate CD40 for tumor-specific immune activation with limited systemic toxicity (Cancer Immunol Res 2019;7:1864). In phase I findings, ABBV-428 was well tolerated up to 3.6mg/kg; 3/50 patients had long-term stable disease (SD; Luke et al. ESMO 2019).

该 I 期研究评估了 ABBV-428 的安全性、耐受性、初步抗肿瘤活性和初步生物标志物，ABBV-428 是一流的间皮素靶向双特异性抗体，专为肿瘤微环境依赖性 CD40 激活而设计，具有有限的全身毒性。

2021年2月1日 · This phase I study assessed the safety, tolerability, preliminary antitumor activity, and preliminary biomarkers of ABBV-428, a first-in-class, mesothelin-targeted, bispecific antibody designed...

我们对LB-1的研究结果被用于开发靶向人CD40和间皮素的人交叉反应双特异性分子（ABBV-428）。 当与细胞表面间皮素结合后，ABBV-428表现出增强的抗原呈递细胞和T细胞活化，并在免疫活化后抑制培养或植入的PC3肿瘤细胞生长。

Upon administration of anti-CD40/anti-TAA bispecific monoclonal antibody ABBV-428, the anti-TAA moiety targets and binds to the TAA expressed on the tumor cells. The agonistic anti-CD40 moiety targets and binds to various CD40-expressing immune cells.

ABBV-428是由艾伯维研发的一种双特异性抗体，是一种CD40激动剂。 目前该药物最高研发阶段为无进展，用于治疗实体瘤。